Provided by Tiger Fintech (Singapore) Pte. Ltd.

Super League Gaming Inc.

4.15
-0.1500-3.49%
Post-market: 4.160.0100+0.24%19:56 EDT
Volume:33.07K
Turnover:139.21K
Market Cap:3.67M
PE:-0.06
High:4.39
Open:4.20
Low:4.07
Close:4.30
Loading ...

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

GlobeNewswire
·
24 Jul

AstraZeneca’s Observational SLE Study in Kazakhstan: Key Insights for Investors

TIPRANKS
·
22 Jul

Cabaletta Bio’s RESET-SLE Study: A Promising Step in Lupus Treatment

TIPRANKS
·
22 Jul

AstraZeneca’s SLE Study in Russia: A Potential Game Changer for Autoimmune Insights

TIPRANKS
·
19 Jul

Super League Enterprise Registers $20 Million in Common Shares for Potential Resale

MT Newswires Live
·
18 Jul

Super League Enterprise files to sell $20M in common stock for holders

TIPRANKS
·
18 Jul

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

GlobeNewswire
·
17 Jul

AstraZeneca’s New CAR T Therapy Study: A Potential Game-Changer for Refractory SLE

TIPRANKS
·
17 Jul

Hong Kong Stocks Movement: SINOMAB BIO-B (03681) Soars Over 18% After Withdrawing RA Treatment Application; Drug Shows SLE Potential

Deep News
·
16 Jul

SINOMAB BIO-B (03681) Surges Over 18% After Withdrawing Sucirasertib RA Application, Retains SLE Treatment Potential

Stock Track
·
16 Jul

AstraZeneca’s INTERSTELLAR Study: Real-World Insights into Anifrolumab for SLE

TIPRANKS
·
16 Jul

AbbVie’s Phase 3 Study on Upadacitinib for SLE: Key Insights for Investors

TIPRANKS
·
15 Jul

Super League Enterprise Inc trading halted, volatility trading pause

TIPRANKS
·
14 Jul

Super League Enterprise Inc. Announces Debt Conversion and Cash Payments Agreement with Michael Keller Trust

Reuters
·
12 Jul

Super League Enterprise Inc. Regains Compliance with Nasdaq Listing Rule After Stock Price Recovery

Reuters
·
09 Jul

Super League Enterprise Inc. Announces Resignation of Board Member Michael Keller Effective June 2025

Reuters
·
08 Jul

Biogen’s Litifilimab Study: A Long-Term Look at SLE Treatment

TIPRANKS
·
04 Jul

GSK’s New SLE Drug Study: What Investors Need to Know

TIPRANKS
·
27 Jun

AbbVie’s Upadacitinib Study: A Potential Game-Changer for SLE Treatment

TIPRANKS
·
27 Jun

AstraZeneca’s AZAHAR Study: Evaluating Anifrolumab’s Real-World Impact on SLE

TIPRANKS
·
25 Jun